Tracking outcomes in adults with hepatitis B liver failure
Part of Digestive system, Infections clinical trials.
This study looks at long-term survival in people ages 18–65 who are hospitalized with hepatitis B–related acute-on-chronic liver failure. It may help doctors better predict prognosis and improve care for people with this serious condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You were diagnosed with hepatitis B–related acute-on-chronic liver failure
- After hospital admission, your survival is expected to be longer than 90 days
- Your inpatient hospital records and key clinical data are complete
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study builds a group of people to measure small hepatitis B “viral RNA” signals in the blood. The goal is to see if these measurements could help researchers find a functional cure and better understand who may respond over time.
This study looks at how patients with chronic hepatitis B are managed when they visit non-liver clinics. It aims to improve care and may also include a survey about quality of life for those starting treatment.
This study looks at how different outcomes of chronic hepatitis B treatment affect patients' quality of life. It includes people who have been functionally cured, those still on treatment, those who relapsed, and healthy controls to compare.
This study follows people who have chronic hepatitis B and also have fat buildup in the liver (nonalcoholic fatty liver disease). It’s looking at how these conditions behave over time and what may help, using information collected during follow-up visits.
This “real-life” study follows people with chronic hepatitis B to better understand their health over time. It may help researchers learn which factors affect outcomes in everyday care.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.